BioLargo, Inc. Announces FDA 510(k) Clearance for Clyra Medical Technologies with The Stock Day Podcast
Phoenix, Arizona--(Newsfile Corp. - October 1, 2019) - The Stock Day Podcast welcomed BioLargo, Inc. (OTCQB: BLGO), an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. CEO Dennis Calvert joined Stock Day host Everett Jolly.
To begin the interview, Jolly noted that BioLargo has experienced a substantial increase in revenue over the past year. Jolly then asked about the company's subsidiary, Clyra Medical Technologies, which recently received its FDA 510(k) clearance. Calvert explained that BioLargo had invested significant capital and time into receiving FDA clearance for its wound irrigation system with Clyra Medical Technologies. "We own about 40% of Clyra Medical Technologies and are also a license holder, so we'll have a royalty on sales," explained Calvert. He then added that this product will lead to the development of at least seven additional products. "This is a multi-billion dollar industry."
Jolly then asked about the potential of the Company's wound irrigation system in comparison with their CupriDyne Clean Industrial Odor Eliminator, which has been highly successful. "When you compare that market to the advanced wound care field, you're talking about a value proposition where we're saving lives and limbs," explained Calvert. "The opportunity to create revenues and profit is astronomically higher."
The conversation then turned to BioLargo's potential partnership with BKT Co. Ltd and the City of Daegu. Calvert shared that BKT Co. Ltd reached out to the company after recognizing mutual goals and values. After forming a closer relationship, both parties believe that a partnership would be extremely beneficial. Calvert also shared that the City of Daegu, South Korea is interested in utilizing the Company's CupriDyne® Clean system for its wastewater treatment.
Jolly then asked for an overview on the BioLargo's varying divisions. Calvert explained that the company focuses on creating innovative and sustainable solutions which can be leveraged to generate revenue all around the world. This is reflected through the BioLargo's diverse set of products, which include solutions in the odor control industry, water treatment industry, and advanced wound care industry.
To close the interview, Calvert shared that the company's technologies are finally starting to prove both its significance and effectiveness. "Now it's all about finding the right partners, making the right moves, making sure we're capitalized properly, and building out some infrastructure," stated Calvert.
To hear Dennis Calvert's entire interview, follow the link to the podcast here: https://audioboom.com/posts/7384128-biolargo-inc-announces-fda-510-k-clearance-for-clyra-medical-technologies-with-the-stock-day-p
About BioLargo, Inc.
BioLargo, Inc. is an innovative technology developer and environmental engineering company driven by a mission to "make life better" by delivering robust, sustainable solutions for a broad range of industries and applications, with a focus on clean water, clean air, and advanced wound care. We develop and commercialize disruptive technologies by providing the capital, support, and expertise to expedite them from "cradle" to "maturity" (www.biolargo.com). Our engineering division features experienced professional engineers dedicated to integrity, reliability, and environmental stewardship (www.biolargoengineering.com). Our industrial odor control division, Odor-No-More (www.odornomore.com) features CupriDyne Clean Industrial Odor Eliminator (www.cupridyne.com), which eliminates the odor-causing compounds and VOCs rather than masking them, and is now winning over leading companies in the solid waste handling and wastewater industries and other industries that contend with malodors and VOCs. Our subsidiary BioLargo Water (www.biolargowater.ca) develops the Advanced Oxidation System "AOS," a disruptive industrial water treatment technology designed to eliminate waterborne pathogens and recalcitrant contaminants with better energy-efficiency and lower operational costs than incumbent technologies. Our subsidiary Clyra Medical (www.clyramedical.com) features effective and gentle solutions for chronic infected wounds to promote infection control and regenerative tissue therapy.
Dennis P. Calvert
President & CEO, BioLargo, Inc.
Safe Harbor Act
This press release includes "forward-looking statements" within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Actual results may differ from expectations, estimates and projections and, consequently, you should not rely on these forward-looking statements as predictions of future events. Words such as "expect," "estimate," "project," "budget," "forecast," "anticipate," "intend," "plan," "may," "will," "could," "should," "believes," "predicts," "potential," "continue," and similar expressions are intended to identify such forward-looking statements. These forward-looking statements involve significant risks and uncertainties that could cause the actual results to differ materially from the expected results
About The "Stock Day" Podcast
Founded in 2013, Stock Day is the fastest growing media outlet for Nano-Cap and Micro-Cap companies. It educates investors while simultaneously working with penny stock and OTC companies, providing transparency and clarification of under-valued, under-sold Micro-Cap stocks of the market. Stock Day provides companies with customized solutions to their news distribution in both national and international media outlets. The Stock Day Podcast is the number one radio show of its kind in America. Stock Day recently launched its Video Interview Studio located in Phoenix, Arizona.
Stock Day Media
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/48367